Compare HROW & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | OMCL |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | N/A | 2000 |
| Metric | HROW | OMCL |
|---|---|---|
| Price | $31.15 | $44.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $69.86 | $55.83 |
| AVG Volume (30 Days) | ★ 842.7K | 589.8K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $787,309,000.00 |
| Revenue This Year | $31.62 | $6.77 |
| Revenue Next Year | $50.77 | $5.22 |
| P/E Ratio | ★ N/A | $175.16 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $25.21 | $26.85 |
| 52 Week High | $54.98 | $51.84 |
| Indicator | HROW | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 63.92 |
| Support Level | $29.15 | $44.17 |
| Resistance Level | $41.67 | $45.17 |
| Average True Range (ATR) | 1.87 | 1.51 |
| MACD | -0.85 | -0.09 |
| Stochastic Oscillator | 18.64 | 86.34 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.